{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-25-000107","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.120928+00:00","generated_at":"2026-05-17T19:50:29.127293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M","bullets":["Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.","Net loss $20.3M ($0.48 loss per share) vs $33.3M ($0.88) in Q2 2024.","Gross-to-net discount ~45%; DTC campaign drove 400% web engagement and 30% more prescribers.","Cash $381.1M; pipeline: Phase 2 TP-04 (ocular rosacea) H2 2025, TP-05 (Lyme) in 2026.","Global expansion: Japan regulatory meetings H2 2025; EU approval expected 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-25-000107","json":"https://secwatch.observer/filing/0001819790-25-000107.json","markdown":"https://secwatch.observer/filing/0001819790-25-000107.md","text":"https://secwatch.observer/filing/0001819790-25-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/0001819790-25-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/tars-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:50:29.127293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}